Hema Now
In this episode of Hema Now, Manali Kamdar explores the rapidly evolving treatment landscape for lymphoma. From the transformative impact of CAR-T cell therapy and the emergence of bispecific antibodies to the challenges of treatment sequencing, toxicity management, and equitable patient access, Kamdar shares her insights into the latest clinical advances. She also discusses the promise of precision medicine, the importance of clinical trials, and her vision for the future of lymphoma care.
Spotify | Apple | Amazon Music | YouTube | Download MP3
Manali Kamdar is the Associate Professor of Medicine and Clinical Director of the Lymphoma Program at the University of Colorado School of Medicine, Aurora, USA. Kamdar is internationally recognised for her expertise in lymphoma, cellular therapies, and novel immunotherapeutic approaches, with a particular focus on improving outcomes for patients with relapsed and refractory lymphomas. Her work has contributed significantly to advancing CAR-T cell therapy and optimising treatment strategies across aggressive B cell malignancies.
Timestamps:
00:00 – Introduction
01:04 – Journey Into Lymphoma Research
05:55 – Key Advances In CAR-T
08:24 – Unmet Needs in Relapsed Lymphoma
12:16 – Bispecifics And CAR-T Integration
15:21 – Sequencing Therapies in Lymphoma
18:40 – Improving Access To CAR-T
21:05 – Managing Cellular Therapy Toxicities
24:29 – Personalised Lymphoma Treatment Progress
28:24 – Current Clinical Research Priorities
33:33 – Three Wishes for Lymphoma Care
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
Keywords: Lymphoma, CAR-T cell therapy, bispecific antibodies, relapsed lymphoma, refractory lymphoma, cellular therapy, immunotherapy, precision medicine, haematology, clinical trials, B-cell lymphoma, oncology, biomarkers, patient access, toxicity management
